United Arab Emirates Pharmacogenetic Testing Market to 2032
Overview
The United Arab Emirates Pharmacogenetic Testing Market is expected to reach a 33.87 USD Million by 2032 and is projected to grow at a CAGR of 7.22% from 2025 to 2032.
Revenue, 2024 (USD Million)
22.48
Forecast, 2032 (USD Million)
33.87
CAGR, 2024 - 2032
7.22%
Report Coverage
United Arab Emirates
United Arab Emirates Pharmacogenetic Testing Market 2018-2032 USD Million
United Arab Emirates Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 22.48 USD Million
- Projected Market Size (2032): 33.87 USD Million
- CAGR (2025-2032): 7.22%
Key Findings of United Arab Emirates Pharmacogenetic Testing Market
- The United Arab Emirates Pharmacogenetic Testing Market was valued at 22.48 USD Million in 2024.
- The United Arab Emirates Pharmacogenetic Testing Market is likely to grow at a CAGR of 7.22% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 12.94 USD Million
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 12.62% during the forecast period from 2024 to 2032.
United Arab Emirates Pharmacogenetic Testing Market Scope
United Arab Emirates Pharmacogenetic Testing Market Segmentation & Scope
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
United Arab Emirates Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 22.48 USD Million |
| Market Value in 2032 | 33.87 USD Million |
| CAGR (2025-2032) | 7.22% |
| Historic Data | 2016-2023 |
| Market Segments Covered | End User,Application,Therapeutic Area,Distribution Channel,Gene,Type,Sample,Drug |
Regional Insights:
-
Leading Market (2024-2032): United Arab Emirates, leading in terms of revenue 22.48 USD Million in 2024
- Key Country: United Arab Emirates, leading in terms of revenue with value of 22.48 USD Million in 2024.
Segments and Scope
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 9.91 USD Million in the year 2024.
- Healthcare Providers is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 7.84 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 10.93 USD Million in the year 2024.
- Clinical Practice is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 7.65 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 4.58 USD Million in the year 2024.
- Cardiology is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 10.36 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 10.96 USD Million in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 7.71 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 3.86 USD Million in the year 2024.
- CYP2C19 is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 12.62 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 11.50 USD Million in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 7.70 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 12.94 USD Million in the year 2024.
- Blood is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 7.38 % in forecast period 2025-2032.
-
United Arab Emirates Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a revenue of 7.99 USD Million in the year 2024.
- Prescription Drugs is the Fastest growing segment in United Arab Emirates Pharmacogenetic Testing Market to 2032 with a Growth rate of 8.21 % in forecast period 2025-2032.
United Arab Emirates Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
United Arab Emirates Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Million
United Arab Emirates Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The United Arab Emirates Pharmacogenetic Testing Market is segmented based on Segmentation End User,Application,Therapeutic Area,Distribution Channel,Gene,Type,Sample,Drug.
United Arab Emirates Pharmacogenetic Testing Market was valued at USD 22.48(Revenue in USD Million) in 2021.
United Arab Emirates Pharmacogenetic Testing Market is projected to grow at a CAGR of 7.22% during the forecast period of 2024 to 2032.
The Blood segment is expected to dominate the United Arab Emirates Pharmacogenetic Testing Market, holding a largest market share of 12.94 USD Million in 2024
United Arab Emirates Pharmacogenetic Testing Market Scope
United Arab Emirates Pharmacogenetic Testing Market Segmentation & Scope
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Sample
- Saliva
- Blood
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Frequently Asked Questions
The United Arab Emirates Pharmacogenetic Testing Market is segmented based on Segmentation End User,Application,Therapeutic Area,Distribution Channel,Gene,Type,Sample,Drug.
United Arab Emirates Pharmacogenetic Testing Market was valued at USD 22.48(Revenue in USD Million) in 2021.
United Arab Emirates Pharmacogenetic Testing Market is projected to grow at a CAGR of 7.22% during the forecast period of 2024 to 2032.
The estimated market value of the United Arab Emirates Pharmacogenetic Testing Market for final year is USD 33.87 (USD Million).
United Arab Emirates Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
The United Arab Emirates Pharmacogenetic Testing Market is segmented based on Segmentation End User,Application,Therapeutic Area,Distribution Channel,Gene,Type,Sample,Drug.
United Arab Emirates Pharmacogenetic Testing Market was valued at USD 22.48(Revenue in USD Million) in 2021.
United Arab Emirates Pharmacogenetic Testing Market is projected to grow at a CAGR of 7.22% during the forecast period of 2024 to 2032.
The estimated market value of the United Arab Emirates Pharmacogenetic Testing Market for final year is USD 33.87 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.